SMTL ID : 3b2r.2 (1 other biounit)

Crystal Structure of PDE5A1 catalytic domain in complex with Vardenafil

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.07 Å

Oligo State

monomer

Ligands

1 x VDN: 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE(Non-covalent)

VDN.1: 14 residues within 4Å: Chain A: Y.82, H.83, C.147, I.150, L.235, A.237, I.238, A.249, V.252, I.283, M.286, Q.287, G.289, F.290 12 PLIP interactions: 12 interactions with chain A Hydrophobic interactions: A:Y.82, A:I.150, A:A.237, A:I.283, A:M.286, A:F.290, A:F.290 Hydrogen bonds: A:Q.287 Water bridges: A:Y.82, A:Q.245 pi-Stacking: A:F.290, A:F.290

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Wang, H. et al., Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol.Pharmacol. (2008)

Release Date

2008-05-20

Peptides

cGMP-specific 3',5'-cyclic phosphodiesterase: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

cGMP-specific 3',5'-cyclic phosphodiesterase

Related Entries With Identical Sequence